N@N

Halozyme Therapeutics Inc (NASDAQ:HALO), Up By 13.17% ($0.98) After BUYINS.NET SqueezeTrigger Report Released on Monday, Janua

January 15, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Monday, January 14th 2013 at 05:16:00 PST stating that Halozyme Therapeutics Inc (NASDAQ:HALO) was expected to be Up After it crossed above its SqueezeTrigger Price of 7.46 on Monday, January 14th 2013. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=halo&id=340421

From August 2009 to December 2012, an aggregate amount of 144086301 shares of HALO have been shorted for a total dollar value of $1008604107. The HALO SqueezeTrigger price of $7.46 is the volume weighted average price that all shorts are short in shares of HALO. There is still approximately $56,025,000 of potential short covering in shares of HALO.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

Halozyme Therapeutics Inc (NASDAQ:HALO) - Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes various products for patient care. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. The company s Enhanze technology, a proprietary delivery platform enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers recombinant human hyaluronidase, an enzyme that degrades hyaluronan, which is a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of diabetes mellitus; PEGPH20, a new molecular entity that is in Phase I clinical trial for the treatment of solid tumors; and HTI-501, a recombinant human proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy (cellulite). It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation to apply Enhanze technology to the partners biological therapeutic compounds. The company was founded in 1998 and is based in San Diego, California..

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---